https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gene-therapy-trial-patients-fanconi-anaemia-open-gosh/
Gene therapy trial for patients with Fanconi anaemia to open at GOSH
22 Mar 2016, 5:24 p.m.
A clinical trial is to open at Great Ormond Street Hospital (GOSH) that will test the use of gene therapy during transplantation for the treatment of young people with Fanconi anaemia. The trial will be led by Dr Claire Booth, Dr Phil Ancliff and Professor Adrian Thrasher – who is the Gene, stem and cellular therapies Theme Lead at the Great Ormond Street BRC.
Fanconi anaemia is a life-limiting, inherited haematological disorder which causes bone marrow failure in childhood as well as other serious complications. Children can be treated with a bone marrow transplant but the success of this procedure depends on finding a well matched donor for the patient.
The clinical trial due to open at GOSH in the coming months will assess whether gene therapy could offer hope to children lacking a suitable donor for transplant.
Researchers will make use of the BRC-funded GMP facility to genetically modify the patient’s own stem cells during the trial.
Teenager off to university after life-changing gene therapy
A teenager with a rare, life-limiting genetic condition is off to university after receiving a gene therapy that changed his life.
Stem cell treatment can improve rare skin condition in children
Children with a rare skin condition have found their symptoms have improved through taking part in the largest clinical trial of its kind, led by clinicians at Great Ormond Street Hospital for Children (GOSH).
Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.
Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.